Sichenzia Ross Ference represented Aegis Capital Corp. as sole book running manager in the underwritten public offering of 9 million shares Common Stock of Opgen, Inc. (NASDAQ: OPGN) at a price of $.60 per share for gross proceeds of $5.4 million.
Opgen is a precision medicine company harnessing the power of molecular diagnostics to combat infectious disease.
The Sichenzia Ross Ference LLP team was led by partners Tom Rose (Picture), Gregory Sichenzia and Jay Yamamoto.
Law Firms: Sichenzia Ross Ference LLP;
Clients: Aegis Capital Corporation;